by Joshua Brown, The Reformed BrokerThe pendulum always swings too far in both directions. I would tell you the ratio of passive fund inflows to active fund inflows over the last few years but I can’t because the latter category would be a negative integer.Instead, I’ll just tell you that almost 100 cents of every dollar has gone into index […]
One of the most popular and well-known names in the biotech world is definitely Biogen (BIIB-Analyst Report). This large cap stock has been a staple of investor portfolios in the biotechnology space for some time, while it is also one of the behemoths of the sector, closing in on $100 billion in market cap.BIIB might be due for a breather […]
Related MAEarnings Scheduled For April 29, 2015MasterCard Earnings Preview: Crowd & Experts Expect 10% EPS GrowthMy Growth Portfolio: Topping Up MasterCard(Seeking Alpha)Related TWXEarnings Scheduled For April 29, 2015Will HBO Now Provide Growth For Time Warner?’Avengers’ Vs. ‘Star Wars’: Which Will Reign Supreme?(Investor’s Business Daily)Some of the stocks that may grab investor focus today are:Wall Street expects Mastercard Inc (NYSE: MA) […]
Submitted by Frank Shostak via The Cobden Centre blog,In a market economy a major service that money provides is that of the medium of exchange. Producers exchange their goods for money and then exchange money for other goods.As production of goods and services increases this results in a greater demand for the services of the medium of exchange (the service […]
Biotech stocks have been on fire in 2015. In the Biotech & Pharmaceuticals sector of the Russell 2000 Growth Index, there are over sixty stocks up by more than 30% this year. More than thirty stocks are up greater than 50% while six have more than doubled.The iShares Biotechnology ETF (IBB) is already up more than 20% less than 3 […]
Since 2008, the ultra-wealthy have been bidding up their own assets, deluding themselves that the fabricated valuations they place on them are real.Momentum bubble visualized:Sales / Price: The amount of revenue for each dollar invested in stocks:http://www.multpl.com/s-p-500-price-to-salesData from WSJ:One year ago, 41 private venture start-ups were valued at $1 billion or more. Now, 75 companies are valued above $1 billion. […]
SummaryThere are many types of risk associated with investing.
Some risks are obvious and straightforward while other risks are far less obvious.
One of the most obvious risks is valuation risk.
As we enter 2015 with a blended P/E ratio of 17, the S&P 500’s valuation sits at the upper end of its historical normal valuation range since 2001.
Current S&P 500 valuation suggests […]
By Louis Navellier, Editor, Blue Chip GrowthTwo of my favorite biotech companies reported third-quarter results today, and they did not disappoint. If you haven’t already picked them up, both of these stocks are solid “buys” at current prices.PLUS: 3 American Financial Stocks to BuyLet’s take a look…Actavis (ACT)Actavis (ACT) surpassed analysts’ sales and earnings expectations for the third quarter. Actavis reported […]
“The Tale of Two Americas” continues to unfold side by side — the better relying on one, investable trend that you can act on today (more on that in a moment).One America is defined by out-of-control debt, wealth consumption, and increasing government control. It’s a doom-and-gloom scenario you’ve likely tried to put out of sight and out of mind, and […]
Growth is good.This week, we’re seeing growth in some unusual places.Gross Domestic Product screamed higher during the second quarter after slumping during the unusually cold winter months. Of course, no one really saw that coming. GDP rose 4%, smashing analyst estimates as Americans bought cars and appliances at the fastest pace in almost five years, Bloomberg reports.Oh, and we’re starting […]